

Novel developments in lower-risk MDS & important practical considerations when treating patients
Jul 15, 2024
In this insightful discussion, Amer Zeidan from Yale and Rena Buckstein from Sunnybrook share their expert views on treating lower-risk myelodysplastic syndromes (MDS). They highlight the importance of accurate diagnosis with bone marrow examinations and prognostic tools. Guillermo Garcia-Manero from MD Anderson dives into innovative treatments like erythropoiesis-stimulating agents and Luspatercept, while Andrew Brunner emphasizes the complexities of dosing. They advocate for improved strategies and collaboration to enhance patient care and outcomes.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7
Intro
00:00 • 2min
Navigating Diagnosis and Treatment in Lower-Risk MDS
01:50 • 2min
Innovative Treatments for Anemic Lower-Risk MDS
03:47 • 13min
Navigating Dosing Complexities in Anemia Treatments
16:46 • 5min
Advancements in Anemia Management for MDS
21:24 • 21min
Exploring Innate Immunity and Treatment Strategies in Low-Risk MDS
41:55 • 4min
Advancements in Low-Risk MDS Treatments
45:59 • 6min